Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143289116> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2143289116 endingPage "720" @default.
- W2143289116 startingPage "716" @default.
- W2143289116 abstract "Daily clinical practice often differs largely from the clinical trial setting, so extrapolation of outcomes from trial data, such as safety, effectiveness, and economic outcomes, can be deceptive. Prescribers may intend to treat a selected group of patients with new drugs; this practice could result in significant bias in assessing outcomes of these agents during their use in daily clinical practice.To evaluate what type of patient received tolterodine compared with the spasmolytic drugs previously marketed (oxybutynin, flavoxate, emepronium).An observational, follow-up study.Eighteen collaborating community pharmacies.Aged > or = 18 years, noninstitutionalized; initial therapy with tolterodine, oxybutynin, flavoxate, or emepronium.Tolterodine was often used as a second-line and even as a third-line treatment, and was prescribed to a polluted population in terms of concomitant psychotropic medication. Tolterodine users were 7.5 times more likely to have received another spasmolytic drug (RR 7.5, 95% CI 4.8 to 11.9). In addition, these patients more frequently used antiparkinsonian drugs (RR 4.1, 95% CI 1.6 to 10.4) as well as antipsychotic drugs (RR 2.9, 95% CI 1.4 to 6.2). There was a small difference in concomitant use of antidepressants and benzodiazepines between patients receiving tolterodine versus those taking other spasmolytic drugs.Tolterodine is prescribed for a population differing from that receiving previously marketed spasmolytic drugs. Selective prescribing should recognized when evaluating new drugs in daily clinical practice. Policy makers, such as pharmacy and therapeutics committees, should consider this aspect in their formulary decisions since selective prescribing can lead to unjustified conclusions about a drug's therapeutic effects (e.g., efficacy, safety, cost-effectiveness)." @default.
- W2143289116 created "2016-06-24" @default.
- W2143289116 creator A5019028031 @default.
- W2143289116 creator A5024588131 @default.
- W2143289116 creator A5035747289 @default.
- W2143289116 creator A5058938491 @default.
- W2143289116 date "2000-06-01" @default.
- W2143289116 modified "2023-09-23" @default.
- W2143289116 title "Selective Prescribing of Spasmolytics" @default.
- W2143289116 cites W1982173583 @default.
- W2143289116 cites W2006236530 @default.
- W2143289116 cites W2059240022 @default.
- W2143289116 cites W2074323366 @default.
- W2143289116 cites W2075325091 @default.
- W2143289116 cites W2080584169 @default.
- W2143289116 cites W2099677238 @default.
- W2143289116 cites W2326054174 @default.
- W2143289116 doi "https://doi.org/10.1345/aph.19267" @default.
- W2143289116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10860131" @default.
- W2143289116 hasPublicationYear "2000" @default.
- W2143289116 type Work @default.
- W2143289116 sameAs 2143289116 @default.
- W2143289116 citedByCount "6" @default.
- W2143289116 crossrefType "journal-article" @default.
- W2143289116 hasAuthorship W2143289116A5019028031 @default.
- W2143289116 hasAuthorship W2143289116A5024588131 @default.
- W2143289116 hasAuthorship W2143289116A5035747289 @default.
- W2143289116 hasAuthorship W2143289116A5058938491 @default.
- W2143289116 hasConcept C104863432 @default.
- W2143289116 hasConcept C126322002 @default.
- W2143289116 hasConcept C142724271 @default.
- W2143289116 hasConcept C177713679 @default.
- W2143289116 hasConcept C204787440 @default.
- W2143289116 hasConcept C2777844464 @default.
- W2143289116 hasConcept C2778941218 @default.
- W2143289116 hasConcept C2779384505 @default.
- W2143289116 hasConcept C2781020410 @default.
- W2143289116 hasConcept C2908647359 @default.
- W2143289116 hasConcept C512399662 @default.
- W2143289116 hasConcept C71924100 @default.
- W2143289116 hasConcept C99454951 @default.
- W2143289116 hasConceptScore W2143289116C104863432 @default.
- W2143289116 hasConceptScore W2143289116C126322002 @default.
- W2143289116 hasConceptScore W2143289116C142724271 @default.
- W2143289116 hasConceptScore W2143289116C177713679 @default.
- W2143289116 hasConceptScore W2143289116C204787440 @default.
- W2143289116 hasConceptScore W2143289116C2777844464 @default.
- W2143289116 hasConceptScore W2143289116C2778941218 @default.
- W2143289116 hasConceptScore W2143289116C2779384505 @default.
- W2143289116 hasConceptScore W2143289116C2781020410 @default.
- W2143289116 hasConceptScore W2143289116C2908647359 @default.
- W2143289116 hasConceptScore W2143289116C512399662 @default.
- W2143289116 hasConceptScore W2143289116C71924100 @default.
- W2143289116 hasConceptScore W2143289116C99454951 @default.
- W2143289116 hasIssue "6" @default.
- W2143289116 hasLocation W21432891161 @default.
- W2143289116 hasLocation W21432891162 @default.
- W2143289116 hasOpenAccess W2143289116 @default.
- W2143289116 hasPrimaryLocation W21432891161 @default.
- W2143289116 hasRelatedWork W2012729846 @default.
- W2143289116 hasRelatedWork W2024445028 @default.
- W2143289116 hasRelatedWork W2110492784 @default.
- W2143289116 hasRelatedWork W2240000265 @default.
- W2143289116 hasRelatedWork W2282921637 @default.
- W2143289116 hasRelatedWork W2297239795 @default.
- W2143289116 hasRelatedWork W2341135423 @default.
- W2143289116 hasRelatedWork W2411479152 @default.
- W2143289116 hasRelatedWork W2604269031 @default.
- W2143289116 hasRelatedWork W4235287135 @default.
- W2143289116 hasVolume "34" @default.
- W2143289116 isParatext "false" @default.
- W2143289116 isRetracted "false" @default.
- W2143289116 magId "2143289116" @default.
- W2143289116 workType "article" @default.